What question did this study set out to answer?

To assess the effectiveness of a dual-drug hydrogel in reversing tumor recurrence and metastasis after surgery.

May 7, 2026ACS Applied Materials & Interfaces1 citations

Meloxicam-1- d -MT Dual-Drug Hydrogel Serves as an Immunomodulator to Reverse Tumor Postoperative Recurrence and Metastasis

XLX W LiCentro de Cirugía de Mínima Invasión Jesús Usón YXYunruo XuWuhan No.1 Hospital LXLuming XuMinistry of Education

Key Points

To assess the effectiveness of a dual-drug hydrogel in reversing tumor recurrence and metastasis after surgery.
Utilized a meloxicam-1-d-mt dual-drug hydrogel postoperatively.
Evaluated T cell activity and levels of antitumor cytokines such as interferon-γ.
Analyzed the reduction of residual tumor burden and recurrence risk.
Demonstrated increased T cell activity post-application of the hydrogel.
Showed elevated levels of interferon-γ following treatment.
Reduced risk of tumor recurrence and metastasis after tumor resection.

Abstract

T cells, as well as elevating antitumor cytokines such as interferon-γ. Overall, combination immunotherapy via the Ge1MT/Mel hydrogel after surgery represents a promising strategy to minimize residual tumor burden and reduce recurrence risk following tumor resection.

AIに質問

Bookmark

View Full Paper